Founder, Chairman, and CEO
Inspired by both his parents’ battle to overcome their affliction with oral cancer, Matthew H.J. Kim founded Vigilant Biosciences, Inc. and currently serves as the company’s Chairman and CEO. Mr. Kim, a seasoned business and legal executive as well as serial entrepreneur, brings experience encompassing IP management, technology transfer, due diligence, business and corporate development. Prior to Vigilant Biosciences, Mr. Kim founded AerovectRx Corporation, the first spin-off company from the Centers for Disease Control and Prevention (CDC) licensing a unique and ground breaking medical device platform technology, raising $1MM+ in a venture staged seed round financing (leveraging an additional $5MM+ in non-dilutive financing), enhancing the company’s IP strategic positioning, and procuring the company’s initial business development deals. Prior to AerovectRx, Mr. Kim founded IP Guidance, a strategic intellectual property asset management consulting group focusing primarily on the management and leverage of IP assets for value creation. Mr. Kim received his Bachelors in Biology at Washington University in St. Louis and his Juris Doctorate at Georgia State University and is licensed to practice in Georgia and before the U.S. Patent and Trademark Office.
Scientific Founder and Chief Scientific Officer
Dr. Franzmann’s innovative clinical research on selective salivary biomarkers for head and neck squamous cell carcinoma serves as the foundation for the company’s initial product. In addition to her clinical research activities, Dr. Franzmann is certified by the American Board of Otolaryngology specializing in otolaryngology and plastic surgery with the head and neck otolaryngology as an Associate Professor of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Franzmann was also recently recognized as one of the "Best Doctors in America 2011-2012", an honor that reflects considered by fellow physicians to be one of the most skilled in her field for and most qualified for reviewing complex medical conditions. Dr. Franzmann received her Bachelor of Science and Doctorate of Medicine at the University of California Los Angeles.
Vice President – Regulatory Affairs
Ms. Bowden has over 20 years of experience in the quality and regulatory field in medical devices, companion diagnostics, education and health care systems. She has served in executive positions as Vice President of Quality Systems and Process Improvement at Ventana Medical Systems and as Vice President of Quality and Regulatory Compliance at Roche Diagnostics Corporation. She was an associate professor for Purdue University School of Engineering and Technology where she developed the Quality Management Curriculum within the Mechanical Engineering Technology department. Ms. Bowden founded Samco & Associates, Inc. in 2009 to provide consulting for companies interested in developing quality systems that meet FDA and global requirements and re-engineer them for efficient, effective compliance in the medical device field for all classes. In addition, she is helping to pioneer the companion diagnostic process in collaboration with pharmaceutical and diagnostic firms while building strong relationships with the applicable regulatory agencies. Ms. Bowden is a graduate of Purdue University School of Engineering.
Chief Dental Officer
In addition to acting as Vigilant’s Chief Dental Officer, Dr. Comisi maintains an active private practice and also serves as President and CEO of Dental Care with a Difference®, PC, and “Knowledge Brings Health”®. As a well-respected key opinion leader and sought-after speaker in the dental industry, Dr. Comisi serves on the Board of several dental organizations including the Academy of General Dentistry and as an editorial board member of two dental publications. His professional certifications, affiliations, and memberships include a Master of the Academy of General Dentistry, Fellowships in the Academy of Dentistry International, the American College of Dentistry, the Pierre Fauchard Academy, the International College of Dentists, National Dental Practice Based Research Network (NDPBRN), and the International and American Association of Dental Research. Dr. Comisi earned Doctorate of Dental Sciences from Northwestern University Dental School and received his Bachelor of Science in Biology at Fordham University. As a cancer survivor, Dr. Comisi is very interested in advancing the science of the early oral cancer identification and improving the awareness of the dental profession.
Chief Financial Officer
Robert T. Hamilton currently serves as the company’s CFO. Mr. Hamilton, a former Big-Four CPA with 15+ years of public co. and venture-backed private portfolio company experience, has worked with companies in e-commerce, health and fitness, technology and retail/wholesale industries. Prior to Vigilant Biosciences, Mr. Hamilton served as CFO of Bridgevine, Inc., a privately held and venture-backed, e-commerce solution that assists Fortune 500 marketers and advertisers with new customer acquisition through a closed-loop platform. He helped Bridgevine complete a financial turnaround and grow revenues profitably to $50+MM. Previously, as CFO of eDiets, Inc. (formerly NASDAQ- DIET), a leading provider of online weight loss solutions serving over 2 million paying clients, he successfully oversaw its B2C and B2B revenues grow 25 times in a profitable manner and led the company’s transition from a self-funded private company to a NASDAQ listing. Mr. Hamilton began his career as an auditor with Arthur Andersen, LLP in Boston. Progressing to audit manager, he serviced multinational SEC and non-public clients in the high technology, manufacturing, retail/wholesale distribution, and hospitality industries. Mr. Hamilton is a Certified Public Accountant and received his Bachelors in Business Administration from Merrimack College.
Member of Board of Directors
Partner and founder of CoreStrength, Inc., a business management and development firm focused on the dental industry, Mr. Goodman brings to Vigilant broad experience in dental manufacturing and distribution. Prior engagements and roles for Mr. Goodman include having served as President of Dent-X, CEO of a leading online dental marketplace business, President of ESPE America and Director of Marketing for Benco Dental. In addition to his experience in the dental industry, Mr. Goodman founded, grew and sold Business Technology Group, a distribution-oriented software developer. He received a B.A. in Accounting and Economics from Muhlenberg College and his MBA in Finance from Northeastern University.
Member of Board of Directors
Dr. Lord currently serves as the Chair of the Board of Directors of Dexcom, as a Director at Stericycle, and serves on advisory boards for Serco PLC (UK), Anthelio Health and Third Rock Ventures. He has earned certificates in Governance and Audit from the Harvard Business School. A nationally recognized leader in innovations in health care, Dr. Lord became the University of Miami’s Chief Innovation Officer when he returned to his alma mater after three decades in healthcare leadership roles, in September 2011. In March 2012, he was named Chief Operating Officer of the Miller School of Medicine and UHealth-University of Miami Health System. He completed a financial turnaround of the Miller School and continues to serve today as a Professor of Pathology. A board-certified forensic pathologist who began his medical career in the U.S. Navy and later served as chief operating officer of the American Hospital Association and several biotech companies, Dr. Lord served as the CEO for Navigenics, Inc. following his tenure as the former chief innovation officer and senior vice president of Humana. During his time at Humana, he created Humana’s Innovation Center, which combines research, technology and consumer experience to promote health and well-being. He also contributed to the field of predictive sciences by using advanced analytics to predict who will become ill in the future and how to prevent disease. Further cementing his ties to UM, he oversaw the creation of the UM/Humana Health Resources Center on the Miller School campus in 2006. Dr. Lord also serves or has served as a member of a number of prestigious boards and organizations, including the Centers for Disease Control and Prevention’s Advisory Committee to the Director; the National Advisory Council for Healthcare Research and Quality, which advises the U.S. Secretary of Health and Human Services; and the Joint Commission on Accreditation of Health Care Organizations. He was a member of the President’s Council at UM, an advisory group of some of the University's most prominent alumni. His previous academic appointments include Dartmouth Medical School, George Washington University and the Eastern Virginia School of Medicine.
Member of Board of Directors
Eric M. Stone possesses fifteen years of domestic and international marketing, business development, and commercial leadership experience in the health and technology sectors. A co-founder of Creative Vascular, Stone is leading the company's foray into needle-free blood drawing in the hospital setting. As Vice President, Sales and Marketing for MolecularHealth, he oversaw the personalized medicine company's marketing efforts in the mechanism-based drug safety and oncology next generation sequencing markets. With Abbott Laboratories, Stone launched the market-leading drug eluting stent, XIENCE PRIME™, while based in Brussels, Belgium, and the world’s first completely bioresorbable coronary stent, ABSORB™. He also served as the Principal and Founder of a Boston-based organizational effectiveness and strategic marketing boutique consultancy. A founding member of Model N’s (NYSE: MODN) Life Sciences division, Stone oversaw the group’s marketing and partnership and alliance functions. Today, Model N provides revenue management software solutions to the world’s leading medical device, biotech and pharmaceutical companies. Stone started his career in Marketing with Austin, Texas-based Trilogy Software. Active in the social sector, he co-founded Harvard’s Student-Alumni Mentoring Initiative and Wharton’s Health Care Board Fellows Program. He is former Committee Chair and Director of Harvard University’s Alumni Association Board of Directors, and played an instrumental role in CCFA’s grassroots campaign resulting in the 2004 passage of the healthcare Research Review Act by U.S. Congress. Stone serves as an Advisor to 3NT Medical and to Empower Interactive, and is Co-Director of PENN’s MyHeartMap Challenge. He holds an MBA in Health Care Management from The Wharton School, a Master’s degree from Harvard University with an interdisciplinary concentration in Human Development & Leadership Studies, and a BA from the University of Pennsylvania.
Board Observer, Florida Institute for Commercialization of Public Research
Ms. Tanner is responsible for research partner institutions and projects throughout southeast Florida. She has extensive experience executing the kinds of initiatives that propel companies more rapidly towards their strategic goals. Prior to joining the Institute, as head of Tanner Growth, she worked with companies' leaders to identify promising and strategically relevant new directions, formulate sound plans to move forward in those directions and to execute de novo launches, mergers or acquisitions, strategic alliances and joint ventures. Previously, as Senior Vice President, Corporate Development and Chief Strategist for eDiets.com, Inc., a leading provider of online weight loss solutions, Ms. Tanner implemented a paradigm-shifting diet licensing initiative, launched the award-winning eDiets Meal Delivery portion-controlled nationwide fresh meal delivery service and accelerated the company's entry into the corporate hosted services market through the acquisition of Nutrio.com. Previously, Ms. Tanner spent thirteen years on Wall Street as an equity analyst and portfolio manager for companies including Salomon Brothers and Fred Alger Management. She then joined the successful turnaround team at Sensormatic Electronics Corporation, a global electronic security company, where she oversaw e-commerce and investor relations. She has made investments in and completed financings totaling hundreds of millions of dollars on behalf of public and private growth companies.